Humatrope 18iu (6mg)

Humatrope 18IU (6mg)

Humatrope 18IU (6mg) is a somatropin injection cartridge manufactured by Lilly. Each single-patient-use cartridge contains 6 mg of somatropin, equivalent to 18 IU of recombinant human growth hormone. The medicine is supplied as a white lyophilized powder that is reconstituted with the accompanying diluent before use.

This 6 mg presentation is specifically designed for use with the compatible HumatroPen 6 mg injection device. The pen itself may be supplied separately, so customers should check the exact package contents before use.

Humatrope 18IU (6mg) Product Details

Brand: Humatrope
Active ingredient: Somatropin
Strength: 18 IU / 6 mg
Product form: Lyophilized powder for injection
Presentation: Single-patient-use cartridge
Manufacturer: Lilly
Route of administration: Subcutaneous injection
Device compatibility: HumatroPen 6 mg
Pack: One 6 mg cartridge with prefilled diluent syringe
Prescription status: Prescription medicine

What’s Included in the 6mg Cartridge Kit?

Humatrope 18IU differs from ordinary vial-based HGH products because the medicine comes in a dedicated cartridge system. The 6 mg cartridge contains the freeze-dried somatropin preparation, while the package also includes a prefilled syringe containing the diluent required for reconstitution.

The cartridge must be matched with the 6 mg version of the HumatroPen. A 6 mg cartridge should not be treated as interchangeable with the 12 mg or 24 mg Humatrope delivery systems. Checking the strength printed on both the cartridge and compatible injection device helps ensure that the correct equipment is being used.

The powder itself should appear white or almost white before mixing. After correct reconstitution, the solution should be inspected before administration. Do not use a cartridge that appears damaged, has passed its expiry date, or produces a solution with an unexpected appearance.

Somatropin in Humatrope

The active substance in Humatrope is somatropin, a recombinant form of human growth hormone produced using recombinant DNA technology. Its amino-acid sequence corresponds to naturally occurring human growth hormone.

Humatrope is a prescription hormone medicine used for specific medically diagnosed growth-hormone-related conditions. Treatment selection depends on factors such as diagnosis, age, clinical assessment, response to therapy, and individual healthcare requirements.

Because the required amount is patient-specific, a fixed dose should not be taken from a general product description. Follow the dosage and administration instructions provided by the prescribing healthcare professional.

Cartridge Preparation and Use

Humatrope 18IU (6mg) is not supplied as a ready-to-inject liquid cartridge. The powder must first be mixed with the diluent supplied for the product according to the official instructions.

The cartridge should not be shaken during preparation. Once it has been correctly reconstituted, it is inserted into the matching HumatroPen 6 mg delivery device. Anyone using the system for the first time should be shown how to prepare and operate the pen by a healthcare professional.

Each cartridge is intended for one patient only. Needles should not be shared, and appropriate injection-site rotation and general medication safety practices should be followed.

Storage of Humatrope 6mg

Temperature control is particularly important for Humatrope. Unused cartridges should be kept refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze the cartridge and do not expose it to unnecessary heat.

According to current product information, the reconstituted cartridge should also be stored refrigerated at 2°C to 8°C and used within the period specified in the supplied instructions. Proper cold storage helps protect the quality of this protein-based medicine.

Before use, check the carton, cartridge strength, expiry date, seals and storage condition. Do not use a cartridge that has been frozen or improperly stored.

Important Safety Information

Humatrope can cause adverse effects and is not appropriate for every patient. Reported reactions associated with somatropin include headache, fluid retention, joint or muscle discomfort, tingling sensations, injection-site changes and alterations in glucose tolerance.

Certain medical conditions can make somatropin unsuitable or require closer medical monitoring. Patients should inform their healthcare provider about existing conditions and other medicines before treatment begins.

Humatrope 18IU (6mg) should be used for an approved medical purpose under appropriate professional supervision. Always follow the prescription, official product information and instructions supplied with the cartridge.